Dynamk Capital — 2021 Investments
1 investments dated 2021 · listed companies and verified rows first · show all
Envisagenics uses AI-driven analysis of RNA splicing to discover novel drug targets for immuno-oncology and neurodegenerative diseases.
AI & Machine LearningBiotechMedical DevicesNew York, US
Maria Pineda, PhD(CEO & Co-founder)Martin Akerman, PhD(CEO & Co-founder)Martin Akerman(Executive Officer, Director, Promoter)Maria Luisa Pineda(Executive Officer, Director, Promoter)Maria Luisa Pineda, PhD.(Founder)in
Co-investorsHAWKTAILM12 (Microsoft's Venture Fund)Madrona Venture GroupRed Cell IncubationDolby Family VenturesThird Kind Venture Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.